CLDI

Calidi is a $1.6M-market-cap clinical-stage biotech that, in its own words, has 'not generated any revenue to date from product sales' and does 'not expect to do so in the foreseeable future.' Its lead RedTail asset, CLD-401, has not even filed an IND — management only 'expect[s] to file an IND for a Phase I trial by the end of 2026.' The only assets in the clinic are a partner-funded (City of Hope) NeuroNova Phase 1 and a SuperNova IND; both are legacy stem-cell-encapsulated platforms the company itself says cannot deliver systemically. So the investable story rests entirely on a preclinical, mouse-model program still 6+ months from its first regulatory filing.

The balance sheet cannot fund that journey. The 10-K carries an explicit going-concern warning: with ~$5.6M cash, a $141.6M accumulated deficit, and ~$2.3M working capital at 12/31/25, management states existing cash 'will not enable us to fund our operating expenses and capital expenditure requirements for the twelve months.' Against a -$21.3M operating cash burn (FY2025), $5.82M of cash is roughly one quarter of runway. Survival requires dilutive raises the filing openly flags — 'debt or equity financings' with 'preferences, superior voting rights, and the issuance of warrants,' plus selling-securityholder registrations that 'will adversely affect the price of our common stock.' A -61.7% share-count change and $-5.95 diluted EPS show a reverse split has already occurred; the setup points to continued dilution into a thin float.